• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

BioInvent International

24.20 SEK

-2.42 %

Less than 1K followers

BINV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.42 %
+1.26 %
+4.31 %
-17.69 %
-14.34 %
-35.98 %
+26.44 %
-58.20 %
-97.46 %

BioInvent International is a biotechnology company focused on the development of antibody therapies for cancer treatment. The company researches new treatments that can improve patient outcomes and quality of life. The company operates globally with a presence in international markets. BioInvent International was founded in 1983 and is headquartered in Lund.

Read more
Market cap
1.59B SEK
Turnover
5.67M SEK
Revenue
226.5M
EBIT %
-155.27 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27/8
2026

Interim report Q2'26

29/10
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/11/2026, 6:00 AM

BioInvents TNFR2-antikropp BI-1808 visar lovande responser och immunaktivering som monoterapi och i kombination med KEYTRUDA® (pembrolizumab) i långt gången CTCL (EHA 2026)

BioInvent International
Press release6/11/2026, 6:00 AM

BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent International
Press release6/11/2026, 6:00 AM

BioInvents trippelkombination med BI-1206 uppnår 83 % responsgrad i behandlingsresistent NHL med förbättrad säkerhetsprofil jämfört med standardbehandling (EHA 2026)

BioInvent International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/11/2026, 6:00 AM

BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)

BioInvent International
Press release6/1/2026, 9:00 AM

BioInvent anordnar KOL-event i Stockholm den 11 juni 2026 för att diskutera uppdaterade data för BI-1206 & BI-1808 inom hematologi

BioInvent International
Press release6/1/2026, 9:00 AM

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

BioInvent International
Regulatory press release5/21/2026, 9:00 PM

BioInvent presenterar solida data på ASCO för behandling av långt framskriden äggstockscancer med TNFR2-antikroppen BI-1808 och KEYTRUDA® (pembrolizumab)

BioInvent International
Regulatory press release5/21/2026, 9:00 PM

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent International
Press release5/20/2026, 9:30 AM

BioInvent anordnar ett digitalt KOL-event för att diskutera BI-1808 för behandling av äggstockscancer, den 27 maj 2026

BioInvent International
Press release5/20/2026, 9:30 AM

BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvents TNFR2-antikropp BI-1808 uppvisar effekt och immunaktivering både som monoterapi och i kombination med KEYTRUDA® (pembrolizumab) vid långt framskriden CTCL (EHA 2026)

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvent’s TNFR2 Antibody BI-1808 Shows Strong Activity and Immune Activation as Single Agent and in Combination with KEYTRUDA® (pembrolizumab) in Advanced CTCL (EHA 2026)

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvent presenterar kliniska data på EHA 2026 för trippelkombinationen med BI-1206 (anti- FcγRIIB), rituximab och Calquence® vid återkommande/refraktär NHL

BioInvent International
Press release5/12/2026, 1:30 PM

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence® in Relapsed/Refractory NHL at EHA 2026

BioInvent International
Regulatory press release4/29/2026, 3:30 PM

Beslut på BioInvents årsstämma 2026

BioInvent International
Regulatory press release4/29/2026, 3:30 PM

Resolutions at BioInvent’s Annual General Meeting 2026

BioInvent International
Press release4/29/2026, 9:35 AM

BioInvent bjuder in till två Key Opinion Leader-event för att belysa utvecklingen i onkologiportföljen

BioInvent International
Press release4/29/2026, 9:35 AM

BioInvent to Host Two Key Opinion Leader Events Highlighting Progress Across Oncology Portfolio

BioInvent International
Regulatory press release4/29/2026, 6:00 AM

BioInvent International AB: Interim report January - March 2026

BioInvent International
Regulatory press release4/29/2026, 6:00 AM

BioInvent International AB: Delårsrapport januari – mars 2026

BioInvent International